CEO statement on the current situation

Erlangen, Germany |  Mar 19, 2020

Ladies and Gentlemen,

I’m turning to you at a time which can be considered extraordinary in every respect – both for you and for us. A regionally limited problem has developed into a pandemic at an unprecedented speed. The spread of COVID-19 poses special challenges for societies around the world and puts the issue of "health" into sharp focus for all of us. For this reason, our approximately 53,000 employees are working harder than ever on what's most important to us: we are helping healthcare providers wherever and whenever possible, so that they can provide the best possible care for their patients.

Our teams have done extraordinary work in China right from the start of the infections, providing our imaging equipment where it is most needed – overnight and across hundreds of kilometers. At our plants in China, we have learned how to continue operations in difficult circumstances. We have so far succeeded - not least because our employees respond quickly and embody our values – in keeping our business stable overall. In part, we are even seeing a significantly increased interest in our imaging equipment.

Our computed tomography (CT) systems are used to monitor patients with acute or impending lung failure and to ensure they receive the necessary therapies - especially in the intensive care treatment of ventilated patients. At the same time, our X-ray and ultrasound devices are used in the overall care process of ill people. We are striving to make sure these devices, as well as blood gas systems for monitoring of ventilated patients, are available wherever infected and sick people need quick and reliable care. We are working every day on further innovations using the latest tools such as algorithms based on artificial intelligence (AI). In the future, these AI algorithms may help to detect damage to lung tissue very quickly in CT images. In addition, our digital services enable medical personnel to operate our systems safely and efficiently, regardless of their location and thus without the risk of infection as well as the development of a SARS CoV-2 virus test that is not tied to a specific analysis platform.

Our aspiration to drive innovations forward so people live healthier and longer lives is more valid today than ever before. We are stepping up as a partner to support healthcare systems. We are working closely with policymakers and healthcare providers around the world to ensure that people have the best possible access to healthcare. Helping people has been the purpose of our company for over 120 years. And that is still true today and in the future!

Yours truly

Bernd Montag

Statement - COVID-19 Business Impact

Siemens Healthineers continues to assess the impact of the COVID-19 pandemic as a priority topic. We are working closely with the NHS and other care providers, as well as our industry partners, to address the unprecedented challenges posed by this crisis. Multiple task force teams across our organisation are meeting daily on the topic, operating at both global and local levels.

In this dynamic and fast moving situation, we remain committed to protecting the health and wellbeing of our employees and others, while continuing to focus on enabling our customers to deliver safe and effective patient care.

We recognise that our customers and their patients are reliant on Siemens Healthineers to provide critical services to support the efforts in combating and treating this disease. We have equipped our workforce to support our customers as productively as possible from home and are enabling critical front-line work to continue where necessary. Additionally, we continue to enhance our infrastructure to quickly address issues remotely in this changing working environment. We are ensuring that we remain agile and pragmatic in responding to the high demands for critical equipment and delivering those solutions as swiftly as possible.

Siemens Healthineers continue to actively monitor both our own and our suppliers‘ operational and manufacturing capabilities to ensure we can provide reliability in a time of uncertainty. Our absolute priority is to support the crisis effort at present. We are proactively working with each customer to optimise support for their situations. At present, we are not experiencing any significant interruptions to supply or delivery due to COVID-19.

Siemens Healthineers remains steadfast in our commitment to the health and safety of everyone, and endeavour to move swiftly and effectively to support the NHS and each other during this time.

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2019, which ended on September 30, 2019, Siemens Healthineers, which has approximately 52,000 employees worldwide, generated revenue of €14.5 billion and adjusted profit of €2.5 billion.
Further information is available at


Stefan Schmidt
Karlheinz Kaske Straße 5
91052 Erlangen

+49 152 02307361

Philipp Grontzki
Karlheinz Kaske Straße 5
91052 Erlangen

+49 152 03350194